These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 3898183)

  • 1. Low- and high-dose naloxone in dementia of the Alzheimer type.
    Tariot PN; Sunderland T; Weingartner H; Murphy DL; Cohen MR; Cohen RM
    Psychopharmacol Bull; 1985; 21(3):680-2. PubMed ID: 3898183
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of naloxone in senile dementia: a double-blind trial.
    Reisberg B; Ferris SH; Anand R; Mir P; Geibel V; De Leon MJ; Roberts E
    N Engl J Med; 1983 Mar; 308(12):721-2. PubMed ID: 6338389
    [No Abstract]   [Full Text] [Related]  

  • 3. Cognitive and behavioral sensitivity to scopolamine in Alzheimer patients and controls.
    Sunderland T; Tariot PN; Mueller EA; Murphy DL; Weingartner H; Cohen RM
    Psychopharmacol Bull; 1985; 21(3):676-9. PubMed ID: 3898182
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of naloxone on acute stroke.
    Czlonkowska A; Cyrta B
    Pharmacopsychiatry; 1988 Mar; 21(2):98-100. PubMed ID: 3293092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naloxone fails to reverse blood pressure in shock: a double blind study in man.
    Montastruc JL; Richard JP; Cathala B
    J Pharmacol; 1985; 16(3):313-4. PubMed ID: 3906280
    [No Abstract]   [Full Text] [Related]  

  • 6. Phosphatidylserine in the treatment of Alzheimer's disease: results of a multicenter study.
    Amaducci L
    Psychopharmacol Bull; 1988; 24(1):130-4. PubMed ID: 3290936
    [No Abstract]   [Full Text] [Related]  

  • 7. Lack of clinical benefit from naloxone in a dementia day hospital.
    Panella JJ; Blass JP
    Ann Neurol; 1984 Mar; 15(3):308. PubMed ID: 6721454
    [No Abstract]   [Full Text] [Related]  

  • 8. [Preliminary results of a long-term double-blind study of naftidrofuryl and a placebo in patients with moderate Alzheimer-type senile dementia].
    Cucinotta D; Dall'Asta D; Benaglia F; Barbagallo M; Butturini L; Pioli G; Salomone M
    G Clin Med; 1985; 66(11-12):467-76. PubMed ID: 3835091
    [No Abstract]   [Full Text] [Related]  

  • 9. A pilot study of serotonergic system responsivity in Alzheimer's disease.
    Lawlor BA; Mellow AM; Sunderland T; Hill JL; Murphy DL
    Psychopharmacol Bull; 1988; 24(1):127-9. PubMed ID: 3290935
    [No Abstract]   [Full Text] [Related]  

  • 10. No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease.
    Wettstein A
    Ann Neurol; 1983 Feb; 13(2):210-2. PubMed ID: 6830183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 4-aminopyridine in elderly patients with Alzheimer's disease.
    Wesseling H; Agoston S; Van Dam GB; Pasma J; DeWit DJ; Havinga H
    N Engl J Med; 1984 Apr; 310(15):988-9. PubMed ID: 6366565
    [No Abstract]   [Full Text] [Related]  

  • 12. Choline in Alzheimer's disease.
    Renvoize EB; Jerram T
    N Engl J Med; 1979 Aug; 301(6):330. PubMed ID: 377082
    [No Abstract]   [Full Text] [Related]  

  • 13. [The use of 1-acetylcarnitine in (presenile and senile) Alzheimer's disease. Preliminary results].
    Acierno G
    Clin Ter; 1983 Apr; 105(2):135-45. PubMed ID: 6345054
    [No Abstract]   [Full Text] [Related]  

  • 14. Naloxone and dementia.
    Stowe C; Gora ML
    Ann Pharmacother; 1993 Apr; 27(4):447-8. PubMed ID: 8477122
    [No Abstract]   [Full Text] [Related]  

  • 15. A neuropsychological test battery for use in Alzheimer disease clinical trials.
    Harrison J; Minassian SL; Jenkins L; Black RS; Koller M; Grundman M
    Arch Neurol; 2007 Sep; 64(9):1323-9. PubMed ID: 17846273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of naloxone in chronic schizophrenia.
    Berger PA; Watson SJ; Akil H; Barchas JD
    Am J Psychiatry; 1981 Jul; 138(7):913-8. PubMed ID: 6266259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naloxone may be beneficial in the treatment of tardive dyskinesia.
    Blum I; Munitz H; Shalev A; Roberts E
    Clin Neuropharmacol; 1984; 7(3):265-7. PubMed ID: 6386154
    [No Abstract]   [Full Text] [Related]  

  • 18. High-dose naloxone in older normal subjects: implications for Alzheimer's disease.
    Tariot PN; Gross M; Sunderland T; Cohen MR; Weingartner H; Murphy DL; Cohen RM
    J Am Geriatr Soc; 1988 Aug; 36(8):681-6. PubMed ID: 3042841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Choline bitartrate treatment of Alzheimer-type dementias.
    Fovall P; Dysken MW; Lazarus LW; Davis JM; Kahn RL; Jope R; Finkel S; Rattan P
    Commun Psychopharmacol; 1980; 4(2):141-5. PubMed ID: 7428335
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.